Uterine sarcomas are rare tumors that account for 3% of uterine cancers. Described risk factors for these tumors include unopposed estrogen stimulation, tamoxifen treatment, obesity, and diabetes. Due to their low incidence and the fact that they lack a preinvasive stage, there is no established practice for screening these tumours. This article focuses on the different therapeutic approaches used for treating these sarcomas.
Uterine sarcomas comprise about 1% of all gynecologic menaces and the incidence of its prevalence ranges between 0.5 and 3.3 cases per 100,000 females per year. Uterine sarcomas exhibit aggressive clinical behavior, with an excessive tendency to local recurrence. Histologically, uterine sarcomas were classified into carcinosarcomas, leiomyosarcomas endometrial stromal sarcomas and undifferentiated sarcomas. However recently, International Federation of Gynecology…
